UroGen

Deal terminate tear up end deal scrap
Biotech

UroGen hands CTLA-4 drug back to Agenus after mulling ph. 1 data

UroGen is handing back an anti-CTLA-4 antibody after concluding that phase 1 data for the bladder cancer drug didn’t warrant further development.
James Waldron Nov 6, 2025 10:00am
pass the torch deal sell buy acquisition

4 years on from launch, IconOVir sells oncolytic virus to UroGen

Feb 20, 2025 9:12am
parachutes sky italy sun blue

Sanofi, Lilly, Amarin & more—Chutes & Ladders

Jun 7, 2024 8:30am